Published in J Med Virol on July 01, 2008
Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst (2010) 3.88
Global proficiency study of human papillomavirus genotyping. J Clin Microbiol (2010) 1.78
Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. J Clin Microbiol (2009) 1.40
Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica. J Infect Dis (2011) 1.25
The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. J Clin Microbiol (2012) 1.24
Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84--results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC Infect Dis (2013) 1.21
Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol (2013) 1.09
Multiple-type human papillomavirus (HPV) infections: a cross-sectional analysis of the prevalence of specific types in 309,000 women referred for HPV testing at the time of cervical cytology. Int J Gynecol Cancer (2013) 1.08
Next-generation sequencing of cervical DNA detects human papillomavirus types not detected by commercial kits. Virol J (2012) 1.08
Global improvement in genotyping of human papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study. J Clin Microbiol (2013) 1.05
Validation of the SPF10 LiPA human papillomavirus typing assay using formalin-fixed paraffin-embedded cervical biopsy samples. J Clin Microbiol (2009) 1.03
Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: a 13-year follow-up. Br J Cancer (2012) 1.01
Performance of commercial reverse line blot assays for human papillomavirus genotyping. J Clin Microbiol (2012) 1.01
Human papillomavirus is not associated with colorectal cancer in a large international study. Cancer Causes Control (2010) 0.98
Acquisition of high-risk human papillomavirus infection in a population-based cohort of Danish women. Sex Transm Dis (2009) 0.96
Validation of human papillomavirus genotyping by signature DNA sequence analysis. BMC Clin Pathol (2009) 0.95
Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus. Med Microbiol Immunol (2009) 0.91
Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with INNO-LiPA HPV genotyping extra assay. J Clin Microbiol (2010) 0.88
Risk for cervical intraepithelial neoplasia grade 3 or worse in relation to smoking among women with persistent human papillomavirus infection. Cancer Epidemiol Biomarkers Prev (2012) 0.88
Prevalence of low-risk HPV types and genital warts in women born 1988/89 or 1983/84 -results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC Infect Dis (2012) 0.87
Effect of HIV Infection on Human Papillomavirus Types Causing Invasive Cervical Cancer in Africa. J Acquir Immune Defic Syndr (2016) 0.84
Molecular tests for human papillomavirus (HPV), Chlamydia trachomatis and Neisseria gonorrhoeae in liquid-based cytology specimen. BMC Womens Health (2009) 0.84
Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with the linear array HPV genotyping PCR assay and influence of DNA extraction method on HPV detection. J Clin Microbiol (2011) 0.83
Human Papillomavirus (HPV) Genotyping: Automation and Application in Routine Laboratory Testing. Open Virol J (2012) 0.82
Comparison of the accuracy of Hybrid Capture II and polymerase chain reaction in detecting clinically important cervical dysplasia: a systematic review and meta-analysis. Cancer Med (2013) 0.82
Distribution of Human Papillomavirus Genotypes in Liquid-based Samples; Abundance of HPV-53 in Tehran, Iran. Iran J Public Health (2014) 0.80
Comparison of human papillomavirus detection between freshly frozen tissue and paraffin embedded tissue of invasive cervical cancer. Infect Agent Cancer (2010) 0.80
HPV genotype detection using hybrid capture sample preparation combined with whole genome amplification and multiplex detection with Luminex XMAP. J Mol Diagn (2010) 0.79
Evaluation of using composite HPV genotyping assay results to monitor human papillomavirus infection burden through simulation. BMC Infect Dis (2015) 0.77
HPV Population Profiling in Healthy Men by Next-Generation Deep Sequencing Coupled with HPV-QUEST. Viruses (2016) 0.77
Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections. J Infect Dis (2016) 0.76
Signature sequence validation of human papillomavirus type 16 (HPV-16) in clinical specimens. J Clin Pathol (2009) 0.75
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006) 5.87
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008) 4.77
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst (2002) 4.43
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst (2011) 3.92
Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst (2010) 3.88
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 3.85
Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis (2011) 3.44
Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol (2006) 3.34
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol (2011) 2.85
Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst (2010) 2.81
Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov (2011) 2.66
Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis (2004) 2.63
The biology and life-cycle of human papillomaviruses. Vaccine (2012) 2.53
Increased incidence of penile cancer and high-grade penile intraepithelial neoplasia in Denmark 1978-2008: a nationwide population-based study. Cancer Causes Control (2011) 2.27
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) (2013) 2.17
The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis (2007) 2.14
Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis (2013) 2.10
Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int J Cancer (2010) 2.08
The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res (2006) 2.08
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One (2013) 2.03
Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol (2002) 1.94
Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol (2005) 1.94
Type-specific HPV infection and multiple HPV types: prevalence and risk factor profile in nearly 12,000 younger and older Danish women. Sex Transm Dis (2008) 1.89
Delta6-desaturase (FADS2) deficiency unveils the role of omega3- and omega6-polyunsaturated fatty acids. EMBO J (2008) 1.72
Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev (2005) 1.71
Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer (2008) 1.71
TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol (2007) 1.70
One virus, one lesion--individual components of CIN lesions contain a specific HPV type. J Pathol (2012) 1.67
Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. J Clin Microbiol (2007) 1.64
Distribution of human papillomavirus in a family planning population in nairobi, kenya. Sex Transm Dis (2003) 1.60
Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2009) 1.59
Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. Int J Cancer (2003) 1.57
New technologies in cervical cancer screening. Vaccine (2008) 1.55
Cutaneous human papillomaviruses found in sun-exposed skin: Beta-papillomavirus species 2 predominates in squamous cell carcinoma. J Infect Dis (2007) 1.54
Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer (2012) 1.48
Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res (2006) 1.47
Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978-2008. Int J Cancer (2011) 1.46
Oncogenic human papillomavirus-infected immature metaplastic cells and cervical neoplasia. Am J Surg Pathol (2014) 1.46
Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev (2007) 1.45
p38gamma MAPK cooperates with c-Jun in trans-activating matrix metalloproteinase 9. J Biol Chem (2010) 1.38
Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa. Int J Cancer (2013) 1.38
Genital warts and risk of cancer: a Danish study of nearly 50 000 patients with genital warts. J Infect Dis (2012) 1.37
The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Res (2003) 1.37
Comparison of three commercially available peptide-based immunoglobulin G (IgG) and IgA assays to microimmunofluorescence assay for detection of Chlamydia trachomatis antibodies. J Clin Microbiol (2002) 1.34
Detection of persistent high risk human papillomavirus infections with hybrid capture II and SPF10/LiPA. J Clin Virol (2005) 1.32
An international external quality assessment of nucleic acid amplification of herpes simplex virus. J Clin Virol (2003) 1.30
Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women. J Natl Cancer Inst (2014) 1.30
Evaluation of a novel highly sensitive, broad-spectrum PCR-reverse hybridization assay for detection and identification of beta-papillomavirus DNA. J Clin Microbiol (2006) 1.29
New technologies and procedures for cervical cancer screening. Vaccine (2012) 1.29
Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol Biomarkers Prev (2006) 1.28
Infection with human papillomavirus and HIV among young women in Kampala, Uganda. J Infect Dis (2008) 1.25
Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol (2014) 1.23
Human papillomavirus (HPV) genotyping using paired exfoliated cervicovaginal cells and paraffin-embedded tissues to highlight difficulties in attributing HPV types to specific lesions. J Clin Microbiol (2007) 1.22
The occasional role of low-risk human papillomaviruses 6, 11, 42, 44, and 70 in anogenital carcinoma defined by laser capture microdissection/PCR methodology: results from a global study. Am J Surg Pathol (2013) 1.21
Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84--results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC Infect Dis (2013) 1.21
Obesity resistance of the stearoyl-CoA desaturase-deficient (scd1-/-) mouse results from disruption of the epidermal lipid barrier and adaptive thermoregulation. Biol Chem (2007) 1.18
Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine (2012) 1.17
High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol (2011) 1.16
Characteristics and survival of head and neck cancer by HPV status: a cancer registry-based study. Int J Cancer (2011) 1.14
Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBO J (2002) 1.14
Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control (2009) 1.14
Triggering of a novel intrinsic apoptosis pathway by the kinase inhibitor staurosporine: activation of caspase-9 in the absence of Apaf-1. FASEB J (2011) 1.14
Human Papillomavirus type distribution in invasive cervical cancer in Uganda. BMC Infect Dis (2008) 1.12
Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions. Cancer Epidemiol Biomarkers Prev (2008) 1.12
Risks for persistence and progression by human papillomavirus type 16 variant lineages among a population-based sample of Danish women. Cancer Epidemiol Biomarkers Prev (2011) 1.11
The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer (2007) 1.10
Direct comparison of HPV16 serological assays used to define HPV-naïve women in HPV vaccine trials. Cancer Epidemiol Biomarkers Prev (2012) 1.09
Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort. J Natl Cancer Inst (2010) 1.09
Human papillomaviruses are identified in a subgroup of sinonasal squamous cell carcinomas with favorable outcome. Cancer (2009) 1.09
Human papillomavirus and the long-term risk of cervical neoplasia. Am J Epidemiol (2002) 1.08
Detection and genotyping of human papillomavirus DNA by SPF10 and MY09/11 primers in cervical cells taken from women attending a colposcopy clinic. J Med Virol (2002) 1.07
Human papillomavirus prevalence and type distribution in 3603 HIV-positive and HIV-negative women in the general population of Tanzania: the PROTECT study. Sex Transm Dis (2012) 1.07
Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: burden and potential for prevention. Int J Cancer (2008) 1.05
Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women. Cancer Epidemiol Biomarkers Prev (2009) 1.03
Determinants of seropositivity among HPV-16/18 DNA positive young women. BMC Infect Dis (2010) 1.03
Population-based study of screening test performance indices of three human papillomavirus DNA tests. J Med Virol (2007) 1.03
NCoR1 mediates papillomavirus E8;E2C transcriptional repression. J Virol (2010) 1.02
Persistence of high-risk human papillomavirus infection in a population-based cohort of Danish women. J Med Virol (2010) 1.02